Rosenberg study opens wider door to personalized TCR therapies for cancer

TIL pioneer Rosenberg study could enable therapies based on T cells from blood rather than tumors

A new study from TIL pioneer Steve Rosenberg adds to the momentum of personalized T cell therapies by suggesting blood can be as good a source of neoantigen-specific TCRs as tumor tissue.

The results, which focused on patients with commonly shared p53 "hotspot" mutations, indicate the potent effects of tumor infiltrating lymphocytes (TILs) on advanced solid tumors could become accessible without invasive surgeries.

That gives Rosenberg's team more options as they develop TCR therapies that bridge the divide between T cells specific for individual patients' neoantigens and off-the-shelf receptors targeting widely shared cancer antigens such as CD19.

"p53 is mutated in about half of all

Read the full 1056 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE